AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$TEVA

Francis Richard D sold $211K of TEVA

Francis Richard D (President and CEO) sold 6,153 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.35 ($0.21M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Francis Richard D
Published Jun 8, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

This provides a fresh, auditable datapoint on insider activity, but the 10b5-1 designation typically limits inference about near-term fundamentals.

02

Market read

A new insider-selling datapoint for TEVA, likely to have only marginal trading impact absent other catalysts.

03

What to watch

Traders may overreact to insider selling; without accompanying operational/regulatory news, the signal is usually weak.

Relevance 3/10Novelty 6/10Timing: filed June 8, covering a June 5 sale

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for TEVA, detailing an officer’s open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

SEC Form 4 shows TEVA CEO Francis Richard D sold 6,153 shares for ~$211.4K on a Rule 10b5-1 plan (open-market sale).

Expected impact

Low likelihood of a sustained price move solely from this disclosure; any reaction is likely brief unless accompanied by other catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, which reduces interpretive weight versus discretionary selling.

Market effects

Sector

No direct sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated beyond potential minor sentiment in US-listed TEVA.

Global

None indicated; transaction is not tied to global operational developments in the text.

Counterpoint

What could challenge this read

Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    TEVA

    TEVA Pharmaceutical Industries Ltd; subject of the Form 4 insider sale disclosure.

  • insider
    Francis Richard D

    President and CEO; reported the sale of 6,153 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

$TEVAMed

Teva Pharmaceutical Industries Ltd (TEVA) Q3 2026 Earnings Call Highlights

Teva Pharmaceutical (TEVA) reported a 2% revenue decline in Q3 2026, driven by a 16% drop in generics revenue. The company discontinued a Phase II study and faces challenges with AUSTEDO revenue due to pricing pressures. CEO Richard Francis and CFO Eli Kalif discussed gross margin expansion, IRA impact, and growth drivers like UZEDY, AJOVY, and WELTRUZA. Teva expects AUSTEDO to reach $2.5B in 2027 and over $3B at peak, despite litigation risks and biosimilar challenges.

finance.yahoo.com
$TEVAHighAI 8/10

H.C. Wainwright raises Teva Pharma stock price target to $54

H.C. Wainwright raised Teva's (NYSE:TEVA) price target to $54 from $52, citing strong Q3 results. Revenue was $4.395B (down 2% YoY, up 6% sequentially), and EPS was $0.86 (beating estimates). The company raised its full-year revenue guidance to $16.7B-$17.0B. Austedo, Ajovy, and Uzedy drove higher expectations. BofA Securities also raised its target to $48.

investing.com
$TEVAMed

Teva’s $420M Samsung Bioepis Deal Includes Biosimilar Banned From US Until 2029 Patent Expires

Teva and Samsung Bioepis agreed to a $420M deal for two biosimilars. Teva gains US rights to RENFLEXIS (infliximab-abda), which can be sold immediately, and ETICOVO (etanercept-ykro), blocked from US sales until 2029 due to patent disputes. The deal includes upfront, launch, and sales milestones. Teva aims to leverage its distribution network to boost RENFLEXIS's market share, while ETICOVO's launch is delayed by legal restrictions.

techtimes.com